We provide you with 20 years of free, institutional-grade data for HROW stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of HROW. Explore the full financial landscape of HROW stock.
Total insider purchase within 3 month on this page: $468,720
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| SILVERNAIL LAUREN P | Open Market Purchase | 1,000 | $31 | 2026-05-19 | |
| Graves Adrienne L | Open Market Purchase | 1,000 | $31.07 | 2026-05-19 | |
| BOLL ANDREW R. | Open Market Purchase | 3,500 | $29.9 | 2026-05-15 | |
| BAUM MARK L | Open Market Purchase | 10,000 | $30.2 | 2026-05-15 | |
| Opaleye Management Inc. | Sale | -5,572 | $39.15 | $218,157 | 2026-03-05 |
| Opaleye Management Inc. | Sale | -193,000 | $39.15 | $7,556,413 | 2026-03-05 |
| Opaleye Management Inc. | Sale | -5,000 | $54.18 | $270,900 | 2026-03-03 |
| Opaleye Management Inc. | Sale | -20,000 | $53.35 | $1,066,914 | 2026-01-08 |
| BOLL ANDREW R. | Sale | -26,665 | $47.06 | $1,254,855 | 2025-12-16 |
| BOLL ANDREW R. | Derivatives Exercise | 60,000 | 2025-12-16 | ||
| BAUM MARK L | Sale | -79,994 | $47.06 | $3,764,518 | 2025-12-16 |
| BAUM MARK L | Derivatives Exercise | 180,000 | 2025-12-16 | ||
| BAUM MARK L | Open Market Purchase | 7,500 | $8.11 | 2023-11-16 | |
| Opaleye Management Inc. | Open Market Purchase | 25,000 | $8.03 | 2023-11-16 | |
| SAHAREK JOHN P. | Sale | -9,778 | $12.83 | $125,452 | 2023-11-14 |
| SAHAREK JOHN P. | Derivatives Exercise | 20,000 | 2023-11-14 | ||
| Opaleye Management Inc. | Open Market Purchase | 20,000 | $14.65 | 2023-09-20 | |
| BAUM MARK L | Open Market Purchase | 5,800 | $17.05 | 2023-08-15 | |
| Makary Martin A. | Open Market Purchase | 20,000 | $16.92 | 2023-08-15 | |
| BAUM MARK L | Sale | -299,968 | $18.23 | $5,468,417 | 2023-07-20 |
| BAUM MARK L | Derivatives Exercise | 762,300 | 2023-07-20 | ||
| SAHAREK JOHN P. | Sale | -109,080 | $18.23 | $1,988,528 | 2023-07-20 |
| SAHAREK JOHN P. | Derivatives Exercise | 277,200 | 2023-07-20 | ||
| BOLL ANDREW R. | Sale | -136,350 | $18.23 | $2,485,661 | 2023-07-20 |
| BOLL ANDREW R. | Derivatives Exercise | 346,500 | 2023-07-20 | ||
| BAUM MARK L | Sale | -117,633 | $20.97 | $2,466,764 | 2023-04-04 |
| BAUM MARK L | Derivatives Exercise | 180,000 | 2023-04-04 | ||
| BOLL ANDREW R. | Sale | -34,442 | $21.16 | $728,793 | 2023-04-04 |
| BOLL ANDREW R. | Derivatives Exercise | 90,000 | 2023-04-04 | ||
| BAUM MARK L | Sale | -35,179 | $14.76 | $519,242 | 2023-01-03 |
| BAUM MARK L | Derivatives Exercise | 88,000 | 2023-01-03 | ||
| BAUM MARK L | RSU | 88,000 | 2023-01-03 | ||
| BOLL ANDREW R. | Sale | -9,602 | $14.76 | $141,726 | 2023-01-03 |
| BOLL ANDREW R. | Derivatives Exercise | 23,000 | 2023-01-03 | ||
| BOLL ANDREW R. | RSU | 23,000 | 2023-01-03 | ||
| Van Horn R. Lawrence | Open Market Purchase | 1,860 | $13.42 | 2022-12-23 | |
| Makary Martin A. | Open Market Purchase | 25,000 | $13.37 | 2022-12-23 | |
| BOLL ANDREW R. | Open Market Purchase | 2,500 | $13.54 | 2022-12-23 | |
| BAUM MARK L | Open Market Purchase | 25,000 | $13.39 | 2022-12-23 | |
| Opaleye Management Inc. | Open Market Purchase | 16,183 | $10.52 | 2022-12-14 | |
| Opaleye Management Inc. | Open Market Purchase | 415,000 | $10.52 | 2022-12-14 | |
| LINDSTROM RICHARD L MD | Sale | -40,000 | $12.62 | $504,800 | 2022-10-03 |
| Opaleye Management Inc. | Open Market Purchase | 1,085 | $9.77 | 2022-09-30 | |
| Opaleye Management Inc. | Open Market Purchase | 10,000 | $9.77 | 2022-09-30 | |
| Opaleye Management Inc. | Open Market Purchase | 6,389 | $6.75 | 2022-04-13 | |
| Opaleye Management Inc. | Open Market Purchase | 35,000 | $6.75 | 2022-04-13 |
The information provided in this report about HROW stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Harrow Health, Inc(NASDAQ:HROW) 
Harrow Health, Inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company offers ophthalmology based pharmaceutical products; and operates Visionology, an online eye health and medication platform. It also develops and ...
Website: http://www.harrowinc.com
Founded: 2012
Full Time Employees: 133
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic